<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ometendo</journal-id><journal-title-group><journal-title xml:lang="ru">Ожирение и метаболизм</journal-title><trans-title-group xml:lang="en"><trans-title>Obesity and metabolism</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2071-8713</issn><issn pub-type="epub">2306-5524</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/omet13129</article-id><article-id custom-type="elpub" pub-id-type="custom">ometendo-13129</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL STUDIES</subject></subj-group></article-categories><title-group><article-title>К вопросу о роли гиперферритинемии и дисметаболической перегрузки железом в формировании нарушений углеводного обмена у лиц с избыточной массой тела и ожирением</article-title><trans-title-group xml:lang="en"><trans-title>Hyperferritinemia and dysmetabolic iron overload in the formation of carbohydrate metabolism disorders in overweight and obese patients</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7148-6739</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мусина</surname><given-names>Н. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Musina</surname><given-names>N. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мусина Надежда Нурлановна, к.м.н., кафедра факультетской терапии с курсом клинической фармакологии, ассистент</p><p>634050, Томск, Московский тракт, д. 2 </p></bio><bio xml:lang="en"><p>Nadezhda N. Musina, MD, PhD</p><p>2 Moscowski Trakt, 634050 Tomsk</p></bio><email xlink:type="simple">nadiezhda-musina@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9034-7264</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зима</surname><given-names>А. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Zima</surname><given-names>A. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Зима Анастасия Павловна, д.м.н., профессор, кафедра патофизиологии, профессор; Централизованная клинико-диагностическая лаборатория, заведующий</p><p>Томск</p></bio><bio xml:lang="en"><p>Anastasiia P. Zima, MD, PhD, Professor</p><p>Tomsk</p></bio><email xlink:type="simple">zima2302@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2460-467X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Будеева</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Budeeva</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Будеева Светлана Васильевна, кафедра биохимии и молекулярной биологии с курсом клинической лабораторной диагностики, старший преподаватель; Централизованная клинико-диагностическая лаборатория, заместитель заведующего</p><p>Томск</p></bio><bio xml:lang="en"><p>Svetlana V. Budeeva, MD</p><p>Tomsk</p></bio><email xlink:type="simple">budeeva.svetlana@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4670-5076</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Славкина</surname><given-names>Я. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Slavkina</surname><given-names>Ya. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Славкина Яна Сергеевна, кафедра факультетской терапии с курсом клинической фармакологии, аспирант </p><p>Томск</p></bio><bio xml:lang="en"><p>Yana S. Slavkina, MD</p><p>Tomsk</p></bio><email xlink:type="simple">yanochka_31104@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-1887-3782</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Петрухина</surname><given-names>Д. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Petrukhina</surname><given-names>D. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Петрухина Дарья Андреевна, кафедра факультетской терапии с курсом клинической фармакологии, ординатор-аспирант </p><p>Томск</p></bio><bio xml:lang="en"><p>Daria A. Petrukhina, MD</p><p>Tomsk</p></bio><email xlink:type="simple">petrukhina_dasha98@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6994-3950</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Родионова</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Rodionova</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Родионова Оксана Валерьевна, к.м.н. отделение томографических методов исследований, врач-рентгенолог</p><p>Томск</p></bio><bio xml:lang="en"><p>Oksana V. Rodionova, MD, PhD</p><p>Tomsk</p></bio><email xlink:type="simple">rodionova.ov@ssmu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8775-802X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алибиев</surname><given-names>Д. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Alibiev</surname><given-names>D. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Алибиев Думан Ерланович, кафедра лучевой диагностики и лучевой терапии, аспирант</p><p>Томск</p></bio><bio xml:lang="en"><p>Duman E. Alibiev, MD</p><p>Tomsk</p></bio><email xlink:type="simple">aisetyupego777@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0589-0260</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тонких</surname><given-names>О. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Tonkih</surname><given-names>O. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Тонких Ольга Сергеевна, к.м.н. отделение томографических методов исследований, заведующий</p><p>Томск</p></bio><bio xml:lang="en"><p>Olga S. Tonkih, MD, PhD</p><p>Tomsk</p></bio><email xlink:type="simple">ostonkih@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9011-8720</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Саприна</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Saprina</surname><given-names>T. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Саприна Татьяна Владимировна, д.м.н., профессор кафедра факультетской терапии с курсом клинической фармакологии, профессор кафедры, доцент; Эндокринологическая клиника, заведующий клиникой</p><p>Томск</p></bio><bio xml:lang="en"><p>Tatiana V. Saprina, MD, PhD, Professor</p><p>Tomsk</p></bio><email xlink:type="simple">tanja.v.saprina@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Сибирский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Siberian State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>14</day><month>02</month><year>2026</year></pub-date><volume>22</volume><issue>4</issue><fpage>335</fpage><lpage>349</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мусина Н.Н., Зима А.П., Будеева С.В., Славкина Я.С., Петрухина Д.А., Родионова О.В., Алибиев Д.Е., Тонких О.С., Саприна Т.В., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Мусина Н.Н., Зима А.П., Будеева С.В., Славкина Я.С., Петрухина Д.А., Родионова О.В., Алибиев Д.Е., Тонких О.С., Саприна Т.В.</copyright-holder><copyright-holder xml:lang="en">Musina N.N., Zima A.P., Budeeva S.V., Slavkina Y.S., Petrukhina D.A., Rodionova O.V., Alibiev D.E., Tonkih O.S., Saprina T.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.omet-endojournals.ru/jour/article/view/13129">https://www.omet-endojournals.ru/jour/article/view/13129</self-uri><abstract><sec><title>Обоснование</title><p>Обоснование. Заболевания, в основе которых лежит перегрузка железом, — наследственный гемохроматоз, β-талассемия, поздняя кожная порфирия, — ассоциированы с сахарным диабетом 2 типа (СД2), что позволяет предположить роль избытка железа в формировании нарушений углеводного обмена (НУО). Остается дискутабельным вопрос применимости и информативности использования традиционных параметров феррокинетики в качестве предикторов и маркеров диагностики различных НУО.</p></sec><sec><title>Цель</title><p>Цель. Установить взаимосвязи между маркерами феррокинетики и показателями углеводного обмена у лиц с избыточной массой тела и ожирением. Научная гипотеза: нарушение феррокинетики по типу дисметаболической перегрузки железом влияет на риск индукции и прогрессирования НУО независимо от индекса массы тела (ИМТ).</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Пациентам выполнялись антропометрия, забор крови с определением развернутого биохимического анализа, анализа липидного спектра, развернутого общего анализа крови и биохимических показателей обмена железа. С учетом технических возможностей аппарата, ряду вошедших в исследование пациентов выполнена Т2*-магнитно-резонансная релаксометрия для количественной оценки содержания железа в печени.</p></sec><sec><title>Результаты</title><p>Результаты. В исследование включено 108 пациентов. В ходе исследования проводилась стратификация пациентов в группы в зависимости от наличия НУО (без НУО, с нарушением толерантности к глюкозе (НТГ) и с СД2), а также в зависимости от состояния обмена железа (с относительно высоким и относительно низким уровнем ферритина). Уровень ферритина был значимо выше у пациентов с СД2, чем у пациентов с НТГ (298,10 [145,80–336,95] и 124,00 [58,30–170,55] нг/мл соответственно, p=0,029) и лиц без НУО (59,80 [24,10–108,85] нг/мл, p=0,002), и значимо выше у лиц с НТГ в сравнении с пациентами без НУО (p=0,035). Пациенты с содержанием ферритина, превышающим значения 75 перцентиля, имели более высокий уровень гликированного гемоглобина (HbA1c) (5,8 [5,3–6,6] и 5,4 [5,2–5,7]% соответственно, p=0,016). Уровень ферритина обладает высокой информативностью в диагностике СД2: чувствительность 77,8%, специфичность 91% при диагностическом пороге 208,1 нг/мл (площадь под кривой = 0,813; р=0,002). В  диагностике НТГ у лиц с избыточной массой тела и ожирением ферритин обладает также высокой чувствительностью 75%, и специфичностью 84,4%, но при более низком диагностическом пороге — 126,65 нг/мл (площадь под кривой = 0,738; р=0,016).</p></sec><sec><title>Заключение</title><p>Заключение. Уровень гиперферритинемии нарастает по мере прогрессирования дисгликемии. Ферритин является перспективным маркером, обладающим высокой информативностью в диагностике различных нарушений углеводного обмена.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>BACKGROUND</title><p>BACKGROUND: Diseases, which pathogenesis is based on iron overload - hereditary hemochromatosis, β-thalassemia, porphyria cutanea tarda - are associated with type 2 diabetes mellitus; this suggests the role of excess iron in the formation of carbohydrate metabolism disorders (CMD). The question of the possibility and informative content of using traditional ferrokinetics parameters as predictors and markers for diagnosing various CMD remains debatable.</p></sec><sec><title>AIM</title><p>AIM: To establish relationships between ferrokinetics markers and indicators of carbohydrate metabolism in overweight and obese individuals. The scientific hypothesis is that disturbances in ferrokinetics, such as dysmetabolic iron overload, influence the risk of induction and progression of CMD, regardless of body mass index.</p></sec><sec><title>MATERIALS AND METHODS</title><p>MATERIALS AND METHODS: Patients underwent anthropometry, blood sampling with the determination of a detailed biochemical analysis, lipid spectrum analysis, a detailed general blood test and biochemical indicators of iron metabolism. Taking into account the technical capabilities of the device, a number of patients included in the study underwent T2*-magnetic resonance relaxometry of the liver.</p></sec><sec><title>RESULTS</title><p>RESULTS: The study included 108 patients, stratified into groups depending on the presence of CMD (without CMD, with impaired glucose tolerance (IGT) and with T2DM), as well as depending on the iron metabolism (with relatively high and relatively low ferritin levels). Ferritin levels were significantly higher in patients with T2DM than in patients with IGT (298.10 [145.80–336.95] and 124.00 [58.30–170.55] ng/ml, respectively, p=0.029) and persons without CMD (59.80 [24.10–108.85] ng/ml, p=0.002), and significantly higher in persons with IGT compared to patients without CMD (p=0.035). Patients with ferritin levels above the 75th percentile had higher glycated hemoglobin levels (HbA1c) (5.8 [5.3–6.6] and 5.4 [5.2–5.7]%, respectively, p=0.016). Ferritin was highly informative in the diagnosis of T2DM: sensitivity 77.8%, specificity 91% with a diagnostic threshold of 208.1 ng/ml (area under the curve = 0.813; p=0.002). In diagnosing IGT ferritin had a high sensitivity of 75% and specificity of 84.4%, but with a lower diagnostic threshold of 126.65 ng/ml (area under the curve = 0.738; p=0.016).</p></sec><sec><title>CONCLUSION</title><p>CONCLUSION: The level of hyperferritinemia increases as dysglycemia progresses. Ferritin is a promising marker that is highly informative in the diagnosis of various carbohydrate metabolism disorders.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>сахарный диабет 2 типа</kwd><kwd>нарушение толерантности к глюкозе</kwd><kwd>ожирение</kwd><kwd>перегрузка железом</kwd><kwd>ферритин</kwd><kwd>метаболический синдром</kwd></kwd-group><kwd-group xml:lang="en"><kwd>diabetes mellitus type 2</kwd><kwd>impaired glucose tolerance</kwd><kwd>obesity</kwd><kwd>iron overload</kwd><kwd>ferritin</kwd><kwd>metabolic syndrome</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена по инициативе авторов без привлечения финансирования.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Akter S, Nanri A, Kuwahara K, et al. Circulating ferritin concentrations and risk of type 2 diabetes in Japanese individuals. J Diabetes Investig. 2017;8(4):462-470. doi: https://doi.org/10.1111/jdi.12617</mixed-citation><mixed-citation xml:lang="en">Akter S, Nanri A, Kuwahara K, et al. Circulating ferritin concentrations and risk of type 2 diabetes in Japanese individuals. J Diabetes Investig. 2017;8(4):462-470. doi: https://doi.org/10.1111/jdi.12617</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou F, Zhao Z, Tian L, et al. Association of Serum Ferritin Level with Risk of Incident Abnormal Glucose Metabolism in Southwestern China: a Prospective Cohort Study. Biol Trace Elem Res. 2016;169(1):27-33. doi: https://doi.org/10.1007/s12011-015-0393-5</mixed-citation><mixed-citation xml:lang="en">Zhou F, Zhao Z, Tian L, et al. Association of Serum Ferritin Level with Risk of Incident Abnormal Glucose Metabolism in Southwestern China: a Prospective Cohort Study. Biol Trace Elem Res. 2016;169(1):27-33. doi: https://doi.org/10.1007/s12011-015-0393-5</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Yeap BB, Divitini ML, Gunton JE, et al. Higher ferritin levels, but not serum iron or transferrin saturation, are associated with Type 2 diabetes mellitus in adult men and women free of genetic haemochromatosis. Clin Endocrinol (Oxf ). 2015;82(4):525-532. doi: https://doi.org/10.1111/cen.12529</mixed-citation><mixed-citation xml:lang="en">Yeap BB, Divitini ML, Gunton JE, et al. Higher ferritin levels, but not serum iron or transferrin saturation, are associated with Type 2 diabetes mellitus in adult men and women free of genetic haemochromatosis. Clin Endocrinol (Oxf ). 2015;82(4):525-532. doi: https://doi.org/10.1111/cen.12529</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Naeem M, Schipf S, Bülow R, et al. Association between hepatic iron overload assessed by magnetic resonance imaging and glucose intolerance states in the general population. Nutr Metab Cardiovasc Dis. 2022;32(6):1470-1476. doi: https://doi.org/10.1016/j.numecd.2022.02.013</mixed-citation><mixed-citation xml:lang="en">Naeem M, Schipf S, Bülow R, et al. Association between hepatic iron overload assessed by magnetic resonance imaging and glucose intolerance states in the general population. Nutr Metab Cardiovasc Dis. 2022;32(6):1470-1476. doi: https://doi.org/10.1016/j.numecd.2022.02.013</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Park RJ, Moon JD. Low transferrin saturation is associated with impaired fasting glucose and insulin resistance in the South Korean adults: the 2010 Korean National Health and Nutrition Examination Survey. Diabet Med. 2015;32(5):673-678. doi: https://doi.org/10.1111/dme.12643</mixed-citation><mixed-citation xml:lang="en">Park RJ, Moon JD. Low transferrin saturation is associated with impaired fasting glucose and insulin resistance in the South Korean adults: the 2010 Korean National Health and Nutrition Examination Survey. Diabet Med. 2015;32(5):673-678. doi: https://doi.org/10.1111/dme.12643</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Мусина Н.Н., Славкина Я.С., Петрухина Д.А., Зима А.П., Прохоренко Т.С., Саприна Т.В. О роли дисметаболической перегрузки железом в формировании неалкогольной жировой болезни печени и индукции нарушений углеводного обмена. // Ожирение и метаболизм. — 2023. — Т. 20. — №3. — C. 259-268. doi: https://doi.org/10.14341/omet13013</mixed-citation><mixed-citation xml:lang="en">Musina NN, Slavkina YaS, Petrukhina DA, Prokhorenko TS, Zima AP, Saprina TV. The role of dysmetabolic iron overload syndrome in nonalcoholic fatty liver disease and carbohydrate metabolism disorders induction. Obesity and metabolism. 2023;20(3):259-268. (In Russ). doi: https://doi.org/10.14341/omet13013</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Garbowski MW, Carpenter JP, Smith G, et al. Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan. J Cardiovasc Magn Reson. 2014;16(1):40. doi: https://doi.org/10.1186/1532-429X-16-40</mixed-citation><mixed-citation xml:lang="en">Garbowski MW, Carpenter JP, Smith G, et al. Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan. J Cardiovasc Magn Reson. 2014;16(1):40. doi: https://doi.org/10.1186/1532-429X-16-40</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Титова А.М., Труфанов Г.Е., Фокин В.А. Т2* Магнитно-резонансная релаксометрия в количественной неинвазивной оценке перегрузки железом печени и сердца. // Трансляционная медицина. — 2017. — Т.4. — №5. — С.37–45. doi: https://doi.org/10.18705/2311-4495-2017-4-5-37-45</mixed-citation><mixed-citation xml:lang="en">Titova AM, Trufanov GE, Fokin VA. T2* Magnetic-resonance relaxometry in non-invasive quantitative iron overload assessment of liver and heart. Translational Medicine. 2017;4(5):37–45. (In Russ). doi: https://doi.org/10.18705/2311-4495-2017-4-5-37-45</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Отдельнова К.А. Определение необходимого числа наблюдений в социально-гигиенических исследованиях // Сб. трудов 2-го ММИ. 1980. №150(6). С. 18-22.</mixed-citation><mixed-citation xml:lang="en">Otdel’nova KA. Determination of the required number of observations in social and hygienic studies. Sb. trudov 2-go MMI. 1980;150(6):18–22. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Паниотто В.И., Максименко В.С. Количественные методы в социологических исследованиях. — Киев: Наукова Думка. 1982: С.272.</mixed-citation><mixed-citation xml:lang="en">Paniotto VI, Maksimenko VS. Quantitative methods in sociological research. Kiev: Naukova Dumka; 1982:272. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Шестакова М.В., Драпкина О.М., Бакулин И.Г., Галстян Г.Р. и др. Диагностика, лечение и диспансерное наблюдение пациентов с предиабетом в условиях первичной медико-санитарной помощи. Методические рекомендации. М.: ФГБУ «НМИЦ ТПМ» Минздрава России; 2021.</mixed-citation><mixed-citation xml:lang="en">Shestakova MV, Drapkina OM, Bakulin IG, Galstyan GR et al. Diagnostika, lechenie i dispansernoe nablyudenie patsientov s prediabetom v usloviyakh pervichnoj medikosani tarnoj pomoshchi. Metodicheskie rekomendatsii. M.: FGBU «NMITs TPM» Minzdrava Rossii; 2021. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Harrison AV, Lorenzo FR, McClain DA. Iron and the Pathophysiology of Diabetes. Annu Rev Physiol. 2023;85:339-362. doi: https://doi.org/10.1146/annurev-physiol-022522-102832</mixed-citation><mixed-citation xml:lang="en">Harrison AV, Lorenzo FR, McClain DA. Iron and the Pathophysiology of Diabetes. Annu Rev Physiol. 2023;85:339-362. doi: https://doi.org/10.1146/annurev-physiol-022522-102832</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Simcox JA, McClain DA. Iron and diabetes risk. Cell Metab. 2013;17(3):329-341. doi: https://doi.org/10.1016/j.cmet.2013.02.007</mixed-citation><mixed-citation xml:lang="en">Simcox JA, McClain DA. Iron and diabetes risk. Cell Metab. 2013;17(3):329-341. doi: https://doi.org/10.1016/j.cmet.2013.02.007</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Fernández-Real JM, McClain D, Manco M. Mechanisms Linking Glucose Homeostasis and Iron Metabolism Toward the Onset and Progression of Type 2 Diabetes. Diabetes Care. 2015;38(11):2169-2176. doi: https://doi.org/10.2337/dc14-3082</mixed-citation><mixed-citation xml:lang="en">Fernández-Real JM, McClain D, Manco M. Mechanisms Linking Glucose Homeostasis and Iron Metabolism Toward the Onset and Progression of Type 2 Diabetes. Diabetes Care. 2015;38(11):2169-2176. doi: https://doi.org/10.2337/dc14-3082</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Liu J, Li Q, Yang Y, Ma L. Iron metabolism and type 2 diabetes mellitus: A meta-analysis and systematic review. J Diabetes Investig. 2020;11(4):946-955. doi: https://doi.org/10.1111/jdi.13216</mixed-citation><mixed-citation xml:lang="en">Liu J, Li Q, Yang Y, Ma L. Iron metabolism and type 2 diabetes mellitus: A meta-analysis and systematic review. J Diabetes Investig. 2020;11(4):946-955. doi: https://doi.org/10.1111/jdi.13216</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Fernández-Real JM, Manco M. Effects of iron overload on chronic metabolic diseases. Lancet Diabetes Endocrinol. 2014;2(6):513-526. doi: https://doi.org/10.1016/S2213-8587(13)70174-8</mixed-citation><mixed-citation xml:lang="en">Fernández-Real JM, Manco M. Effects of iron overload on chronic metabolic diseases. Lancet Diabetes Endocrinol. 2014;2(6):513-526. doi: https://doi.org/10.1016/S2213-8587(13)70174-8</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Kim CH, Kim HK, Bae SJ, Park JY, Lee KU. Association of elevated serum ferritin concentration with insulin resistance and impaired glucose metabolism in Korean men and women. Metabolism. 2011;60(3):414-420. doi: https://doi.org/10.1016/j.metabol.2010.03.007</mixed-citation><mixed-citation xml:lang="en">Kim CH, Kim HK, Bae SJ, Park JY, Lee KU. Association of elevated serum ferritin concentration with insulin resistance and impaired glucose metabolism in Korean men and women. Metabolism. 2011;60(3):414-420. doi: https://doi.org/10.1016/j.metabol.2010.03.007</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Zhan Y, Tang Z, Yu J. Serum ferritin, diabetes, diabetes control, and insulin resistance. Acta Diabetol. 2014;51(6):991-998. doi: https://doi.org/10.1007/s00592-014-0656-1</mixed-citation><mixed-citation xml:lang="en">Zhan Y, Tang Z, Yu J. Serum ferritin, diabetes, diabetes control, and insulin resistance. Acta Diabetol. 2014;51(6):991-998. doi: https://doi.org/10.1007/s00592-014-0656-1</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Al Akl NS, Khalifa O, Errafii K, Arredouani A. Association of dyslipidemia, diabetes and metabolic syndrome with serum ferritin levels: a middle eastern populationbased cross-sectional study. Sci Rep. 2021;11(1):24080. doi: https://doi.org/10.1038/s41598-021-03534-y</mixed-citation><mixed-citation xml:lang="en">Al Akl NS, Khalifa O, Errafii K, Arredouani A. Association of dyslipidemia, diabetes and metabolic syndrome with serum ferritin levels: a middle eastern populationbased cross-sectional study. Sci Rep. 2021;11(1):24080. doi: https://doi.org/10.1038/s41598-021-03534-y</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Venkatesan P, Varghese J, Arthi TS, et al. Evidence of dysregulated iron homeostasis in newly diagnosed diabetics, but not in pre-diabetics. J Diabetes Complications. 2021;35(9):107977. doi: https://doi.org/10.1016/j.jdiacomp.2021.107977</mixed-citation><mixed-citation xml:lang="en">Venkatesan P, Varghese J, Arthi TS, et al. Evidence of dysregulated iron homeostasis in newly diagnosed diabetics, but not in pre-diabetics. J Diabetes Complications. 2021;35(9):107977. doi: https://doi.org/10.1016/j.jdiacomp.2021.107977</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Qin Y, Huang Y, Li Y, et al. Association between systemic iron status and β-cell function and insulin sensitivity in patients with newly diagnosed type 2 diabetes. Front Endocrinol (Lausanne). 2023;14:1143919. doi: https://doi.org/10.3389/fendo.2023.1143919</mixed-citation><mixed-citation xml:lang="en">Qin Y, Huang Y, Li Y, et al. Association between systemic iron status and β-cell function and insulin sensitivity in patients with newly diagnosed type 2 diabetes. Front Endocrinol (Lausanne). 2023;14:1143919. doi: https://doi.org/10.3389/fendo.2023.1143919</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Пальцев И.В., Калинин А.Л., Мицура В.М. Нарушения углеводного обмена у больных хроническими вирусными гепатитами с мутациями в гене гемохроматоза // Журнал Гродненского государственного медицинского университета. — 2013. — № 1 — С.31-33.</mixed-citation><mixed-citation xml:lang="en">Paltsev IV, Kalinin AL, Mitsura VM. Impairments of carbohydrate metabolism in patients with chronic viral hepatitis with mutations in hemochromatosis gene. Journal of Grodno State Medical University. 2013;1:31-33. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Пальцев И.В., Калинин А.Л., Сницаренко Е.Н. Сывороточный ферритин - предиктор сахарного диабета 2 типа у пациентов с хроническими гепатитами // Проблемы здоровья и экологии. — 2016. — Т.48. — №2 — С.65-68.</mixed-citation><mixed-citation xml:lang="en">Paltsev IV, Kalinin AL, Snitsarenko EN. Serum ferritin as a predictor of diabetes mellitus type 2 in patients with chronic hepatitis. Health and Ecology Issues. 2016;48(2):65-68. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Abril-Ulloa V, Flores-Mateo G, Solà-Alberich R, Manuel-y-Keenoy B, Arija V. Ferritin levels and risk of metabolic syndrome: metaanalysis of observational studies. BMC Public Health. 2014;14:483. doi: https://doi.org/10.1186/1471-2458-14-483</mixed-citation><mixed-citation xml:lang="en">Abril-Ulloa V, Flores-Mateo G, Solà-Alberich R, Manuel-y-Keenoy B, Arija V. Ferritin levels and risk of metabolic syndrome: metaanalysis of observational studies. BMC Public Health. 2014;14:483. doi: https://doi.org/10.1186/1471-2458-14-483</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization: Assessing the Iron Status of Populations. In Geneva: WHO; 2007. Available at http://apps.who.int/iris/bitstream/10665/75368/1/9789241596107_eng.pdf</mixed-citation><mixed-citation xml:lang="en">World Health Organization: Assessing the Iron Status of Populations. In Geneva: WHO; 2007. Available at http://apps.who.int/iris/bitstream/10665/75368/1/9789241596107_eng.pdf</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Root HF. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol. 2010;53(1):3-22. doi: https://doi.org/10.1016/j.jhep.2010.03.001</mixed-citation><mixed-citation xml:lang="en">Root HF. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol. 2010;53(1):3-22. doi: https://doi.org/10.1016/j.jhep.2010.03.001</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Мехтиев С.Н., Мехтиева О.А. Синдром перегрузки железом при хронических заболеваниях печени: фокус на неалкогольную жировую болезнь печени // Лечащий врач. — 2017. — №12 — С. 60-67.</mixed-citation><mixed-citation xml:lang="en">Mechtiev SN, Mechtieva OA. Iron overload syndrome in chronic hepatic diseases: the focus is on non-alcoholic fat hepatic disease. Lechaschi Vrach. 2017;(12):60-67. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Castiella A, Urreta I, Zapata E, et al. Liver iron concentration in dysmetabolic hyperferritinemia: Results from a prospective cohort of 276 patients. Ann Hepatol. 2020;19(1):31-35. doi: https://doi.org/10.1016/j.aohep.2019.07.014</mixed-citation><mixed-citation xml:lang="en">Castiella A, Urreta I, Zapata E, et al. Liver iron concentration in dysmetabolic hyperferritinemia: Results from a prospective cohort of 276 patients. Ann Hepatol. 2020;19(1):31-35. doi: https://doi.org/10.1016/j.aohep.2019.07.014</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
